Primary Biliary Cirrhosis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Primary Biliary Cirrhosis Epidemiology Forecast Report Coverage

Expert Market Research's “Primary Biliary Cirrhosis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of primary biliary cirrhosis. It projects the future incidence and prevalence rates of primary biliary cirrhosis cases across various populations. The study covers age, gender, and type as major determinants of the primary biliary cirrhosis population. The report highlights patterns in the prevalence of primary biliary cirrhosis over time and projects future trends based on multiple variables.

Primary Biliary Cirrhosis Understanding: Disease Overview

Primary biliary cirrhosis is a chronic autoimmune cholestatic liver disease characterized by progressive destruction of small intrahepatic bile ducts. The condition predominantly affects middle-aged women and is strongly associated with antimitochondrial antibodies. Ongoing bile duct injury leads to cholestasis, fibrosis, and potentially cirrhosis or liver failure if untreated. Patients commonly experience fatigue and pruritus, although many remain asymptomatic in early stages. Disease progression varies significantly, and staging is based on biochemical markers and histological findings, emphasizing the importance of early detection and long-term monitoring.

Primary Biliary Cirrhosis Epidemiology Perspective

The primary biliary cirrhosis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the primary biliary cirrhosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for primary biliary cirrhosis and their trends. The primary biliary cirrhosis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The pooled global prevalence of primary biliary cirrhosis is approximately 18.1 cases per 100,000 people.
• The global incidence rate is around 1.8 new cases per 100,000 person‑years annually, indicating this remains a rare disease.
• PBC is typically diagnosed in middle‑aged to older adults, with incidence increasing with age and peaking around ages 60-79 years. It is exceptionally uncommon in young adults under age 25.
• PBC shows a strong female predominance, with women affected far more frequently than men, though the female‑to‑male ratio has been narrowing in recent studies.

Read more about this report - Request a Free Sample

Country-wise Primary Biliary Cirrhosis Epidemiology Segment

The primary biliary cirrhosis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a rare autoimmune liver disorder with notable country-specific patterns. In the United States, published data estimate prevalence at 65.4 per 100,000 women, 12.1 per 100,000 men, and 40.2 overall, with an incidence of 4.5 per 100,000 women, 0.7 per 100,000 men, and 2.7 overall annually, predominantly affecting older adults. Additionally, in the United Kingdom, approximately 20,000 individuals are living with PBC, with an annual incidence of 2-3 per 100,000, and about 90% of cases occur in women, most commonly between 40 and 60 years of age. These figures highlight the need for timely diagnosis and effective disease management.

Primary Biliary Cirrhosis: Treatment Overview

Treatment for primary biliary cirrhosis aims to slow disease progression and manage symptoms. Ursodeoxycholic acid is the first-line therapy and improves biochemical markers and long-term outcomes in most patients. For patients with an inadequate response, obeticholic acid or fibrates may be added to enhance bile acid regulation. Symptom management includes therapies for pruritus and fatigue. In advanced disease, liver transplantation remains the only definitive curative option. Ongoing research focuses on novel bile acid modulators, anti-inflammatory agents, and antifibrotic therapies to improve response rates and prevent progression to cirrhosis.

Key Questions Answered

• What are the key findings of primary biliary cirrhosis epidemiology in the 8 major markets?
• What will be the total number of patients with primary biliary cirrhosis across the 8 major markets during the forecast period?
• What was the country-wise primary biliary cirrhosis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of primary biliary cirrhosis during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of primary biliary cirrhosis during the forecast period of 2026-2035?
• What are the currently available treatments for primary biliary cirrhosis?
• What are the disease risks, signs, symptoms, and unmet needs of primary biliary cirrhosis?

Scope of the Primary Biliary Cirrhosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of primary biliary cirrhosis based on several factors.
• Primary Biliary Cirrhosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The primary biliary cirrhosis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Primary Biliary Cholangitis Therapeutics Market

Primary Biliary Cholangitis Pipeline Analysis